Algeria would not relinquish the use of controversial of chloroquine in the treatment of coronavirus, despite the decision of the world health Organization (WHO) to suspend the clinical trials, said Tuesday a member of the monitoring committee of the pandemic. "We have treated thousands of cases with this drug with much success to date. And we have not noted any adverse reactions ", said to AFP the Dr. Mohamed Bekkat, a member of the scientific committee to follow the evolution of the pandemic Covid-19 in Algeria. "We have not recorded any deaths related to the use of chloroquine," said Dr. Bekkat, who is also president of the Council of the college of physicians algerians.
Read also Coronavirus : Algeria adopts the chloroquine for severe cases
WHO announced on Monday that it had suspended "temporarily" clinical trials with hydroxychloroquine it has with its partners in several countries, as a precautionary measure. This decision follows the publication in the medical journal the Lancet of a study deeming it ineffective, or even harmful, the use of chloroquine or its derivatives, such as hydroxychloroquine, against the new coronavirus.
For Dr. Bekkat, this study "is confusing" because it seems to concern the serious cases for which hydroxychloroquine is no help ". "It should be noted that the use of chloroquine by arab and african countries has proved to be effective when it is used early on ", he explained. Algeria is one of the most affected countries in Africa by the virus. In total, 8 503 cases and 609 deaths have been officially recorded since the 25th of February.
Read also Covid-19 : the choice to be a double-edged sword of chloroquine by Africa